IMBiologics Corp. (KOSDAQ:493280)

South Korea flag South Korea · Delayed Price · Currency is KRW
53,700
-2,000 (-3.59%)
At close: Apr 28, 2026
106.54%
Market Cap 793.48B
Revenue n/a
Net Income n/a
Shares Out 14.78M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,032
Average Volume 175,613
Open 55,900
Previous Close 55,700
Day's Range 51,900 - 55,900
52-Week Range 26,000 - 104,000
Beta n/a
RSI 54.65
Earnings Date n/a

About IMBiologics

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 493280
Full Company Profile

News

There is no news available yet.